41 related articles for article (PubMed ID: 2217462)
1. The staging of M+ disease.
Bouffioux C; Bollack C; Scher H
Prog Clin Biol Res; 1990; 357():185-91. PubMed ID: 2217462
[TBL] [Abstract][Full Text] [Related]
2. The staging of M1 disease: the role of bone scan, Xray and other imaging techniques.
Richards B; Bollack C; Bouffioux C
Prog Clin Biol Res; 1988; 269():233-42. PubMed ID: 3293062
[TBL] [Abstract][Full Text] [Related]
3. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
Morote J; Lorente JA; Encabo G
Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
5. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate].
Morote Robles J; de Torres Mateos JA
Arch Esp Urol; 1989; 42 Suppl 2():124-30. PubMed ID: 2484148
[TBL] [Abstract][Full Text] [Related]
6. [Effort to radically cure stage III and IV esophageal carcinoma with simultaneous radiotherapy and chemotherapy in standard clinical practice].
Farzad M; De Luca MC; Rubino G; Pirtoli L; Pepi F; Sebaste L; Ponticelli P; Atzeni G; Maranzano E; Silvano G
Radiol Med; 2001; 102(1-2):72-7. PubMed ID: 11677442
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
8. [PSA and follow-up after treatment of prostate cancer].
Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
[TBL] [Abstract][Full Text] [Related]
9. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH
Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322
[TBL] [Abstract][Full Text] [Related]
10. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P
Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221
[TBL] [Abstract][Full Text] [Related]
11. Relative reliability of five serially measured markers for prognosis of progression in prostate cancer.
Killian CS; Emrich LJ; Vargas FP; Yang N; Wang MC; Priore RL; Murphy GP; Chu TM
J Natl Cancer Inst; 1986 Feb; 76(2):179-85. PubMed ID: 2418245
[TBL] [Abstract][Full Text] [Related]
12. Cross-comparison of PSA and PAP values in a wide spectrum of prostate cancer conditions.
Tarle M
Anticancer Res; 1988; 8(4):569-72. PubMed ID: 2460018
[TBL] [Abstract][Full Text] [Related]
13. Metastatic workup of patients with prostate cancer employing alkaline phosphatase and skeletal alkaline phosphatase.
Wolff JM; Ittel TH; Borchers H; Boekels O; Jakse G
Anticancer Res; 1999; 19(4A):2653-5. PubMed ID: 10470213
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study-2.
Jørgensen T; Kanagasingam Y; Kaalhus O; Tveter KJ; Bryne M; Skjørten F; Berner A; Danielsen HE
J Urol; 1997 Jul; 158(1):164-70. PubMed ID: 9186346
[TBL] [Abstract][Full Text] [Related]
15. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma.
Levy DA; Slaton JW; Swanson DA; Dinney CP
J Urol; 1998 Apr; 159(4):1163-7. PubMed ID: 9507823
[TBL] [Abstract][Full Text] [Related]
16. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
17. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
Noguchi M; Noda S
J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
[TBL] [Abstract][Full Text] [Related]
18. [Value of determining prostate specific antigen in follow-up of prostatic cancer].
Sadeh AD; Mukamel E; Galili Y; Nussbaum B; Regev D; Servadio C
Harefuah; 1993 Aug; 125(3-4):69-74, 128. PubMed ID: 7693556
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients.
Grande M; Carlström K; Rozell BL; Stege R; Pousette A
Clin Cancer Res; 2000 May; 6(5):1790-5. PubMed ID: 10815899
[TBL] [Abstract][Full Text] [Related]
20. Classification and staging of melanoma.
Gershenwald JE; Buzaid AC; Ross MI
Clin Lab Med; 2000 Dec; 20(4):785-815. PubMed ID: 11221515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
